πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 763 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9572881

Halogenated compounds for photodynamic therapy

NANOQUANTUM SCIENCES, INC. Β· Granted Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9572809

Combination therapy to treat Mycobacterium diseases

SPERO TRINEM, INC. Β· Granted Tue Feb 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9555037

Method of using vasoconstrictive agents during energy-based tissue therapy

Covidien LP Β· Granted Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9551713

Use of a panel of urinary cytokines to predict response to BCG therapy for bladder cancer

The Board of Regents of the University of Texas System Β· Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9549995

Efficient synthesis of ethylenedicysteine-sugar conjugates for imaging and therapy

The Board of Regents of the University of Texas System Β· Granted Tue Jan 24 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9533045

Photothermal therapy using magnetic nanoparticles

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9533025

Method for treating chemotherapy-induced male infertility

The Board of Regents of the University of Texas System Β· Granted Tue Jan 03 2017 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9522137

Methods for dosing an orally active 1,2,4-Oxadiazole for nonsense mutation suppression the

PTC THERAPEUTICS, INC. Β· Granted Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9517275

Targeted therapy for the prevention of restenosis in the cardiovascular system

Northwestern University Β· Granted Tue Dec 13 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 08 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9512401

B and T lymphocyte attenuator marker for use in adoptive T-cell therapy

The Board of Regents of the University of Texas System Β· Granted Tue Dec 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9492564

Dual specific immunotoxin for brain tumor therapy

The United States of America as Represented by the Secretary of Health and Human Services, National Institutes of Health Β· Granted Tue Nov 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9486474

Interstitial therapy for immediate symptom relief and chronic therapy in interstitial cyst

The Regents of the University of California Β· Granted Tue Nov 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9470689

N-cadherin: target for cancer diagnosis and therapy

The Regents of the University of California Β· Granted Tue Oct 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 13 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9458215

Compositions and methods for osteogenic gene therapy

The United States of America as represented by the Department of Veteran Affairs Β· Granted Tue Oct 04 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9458442

Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof

HALOZYME, INC. Β· Granted Tue Oct 04 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9452182

Collateral gene inactivation biomarkers and targets for cancer therapy

The Board of Regents of the University of Texas System Β· Granted Tue Sep 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9433666

Indoleamine 2,3-dioxygenase based immunotherapy

IO Biotech ApS Β· Granted Tue Sep 06 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 01 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9428541

Substrate reduction therapy

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9415123

Polymeric nanoparticles for ultrasound imaging and therapy

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Aug 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9404081

Pyruvate kinase activators for use in therapy

Agios Pharmaceuticals, Inc. Β· Granted Tue Aug 02 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9399662

Concurrent chemotherapy and immunotherapy

The Board of Regents of the University of Texas System Β· Granted Tue Jul 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9375438

Inhibitors of NCCa-ATP channels for therapy

The United States of America as Represented by the Dept. of Veterans Affairs Β· Granted Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9375475

Combination immunotherapy for the treatment of cancer

The Board of Regents of the University of Texas System Β· Granted Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9364462

Alpha-1-adrenergic receptor agonist therapy

The Regents of the University of California Β· Granted Tue Jun 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted